Vellinton Healthcare Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vellinton Healthcare Pharmaceutical Export Portfolio Dataset — 2 Products, $45.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vellinton Healthcare — Pharmaceutical Exporter Profile (2026) | 2 Products, $45.1K Trade | TransData Nexus

Vellinton Healthcare

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $45.1K Total Trade · DGFT Verified

Vellinton Healthcare is an Indian pharmaceutical exporter with a total trade value of $45.1K across 2 products in 2 therapeutic categories. Based on 6 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Morphine ($32.7K), Biotin ($12.4K), .

Vellinton Healthcare — Export Portfolio & Destination Treemap

Vellinton Healthcare pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vellinton Healthcare? — Company Overview & Market Position

Vellinton Healthcare Private Limited, established on August 4, 2015, is a privately held pharmaceutical company headquartered in Kala Amb, Himachal Pradesh, India. The company is registered under the Corporate Identification Number (CIN) U24231HP2015PTC001015. Its authorized capital stands at ₹2.5 crore, with a paid-up capital of ₹0.38 lakh. The leadership comprises Directors Parshotam Lal Goyal, Manic Goyal, and Konic Goyal. Vellinton Healthcare specializes in the manufacturing and export of pharmaceutical products, including small volume parenterals, beta-lactam antibiotics, cephalosporins, and ophthalmic preparations. The company employs approximately 100 personnel and operates three state-of-the-art manufacturing facilities. Vellinton Healthcare is committed to delivering high-quality medicines and supplements, adhering to stringent manufacturing standards.

What Does Vellinton Healthcare Export? — Product Portfolio Analysis

Top Products by Export Value

1Morphine$32.7K 2Biotin

Product Portfolio — Top 2 by Export Value

Vellinton Healthcare exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Morphine	Analgesics & Antipyretics	$32.7K	3	0.2%	11
2	Biotin	Vitamins & Supplements	$12.4K	3	0.8%	5

Vellinton Healthcare exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $45.1K. The top category is Analgesics & Antipyretics (72.4% of portfolio), followed by Vitamins & Supplements (27.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vellinton Healthcare — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vellinton Healthcare operates three advanced manufacturing facilities strategically located in Kala Amb, Himachal Pradesh, India. These facilities are equipped to produce a diverse range of pharmaceutical products, including small volume parenterals (both dry and liquid forms), beta-lactam antibiotics, cephalosporins, and ophthalmic preparations such as eye and ear drops and ointments. The manufacturing units are designed to meet international standards, with plans to acquire certifications such as EU GMP, US FDA, and PIC/S to enhance their global market presence.

3Key Leadership

Vellinton Healthcare is led by Directors Parshotam Lal Goyal, Manic Goyal, and Konic Goyal. Parshotam Lal Goyal serves as the Managing Director, overseeing the company's strategic direction and operations. Manic Goyal and Konic Goyal, as Directors, contribute to the company's growth and development through their expertise and leadership. Their combined leadership has been instrumental in establishing Vellinton Healthcare as a reputable entity in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vellinton Healthcare Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vellinton Healthcare has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities adhere to international standards, with plans to acquire certifications such as EU GMP, US FDA, and PIC/S to enhance their global market presence. Additionally, Vellinton Healthcare has initiated business across regions such as Africa, Latin America, ASEAN, CIS, and MENA, with product registrations and GMP plant inspections underway in various countries. These efforts underscore the company's commitment to meeting the stringent regulatory requirements of these markets.

2Emerging Markets

Vellinton Healthcare has strategically expanded its footprint in emerging markets, including Africa, Latin America, Southeast Asia, and the Middle East. The company has initiated business across regions such as Africa, Latin America, ASEAN, CIS, and MENA, with product registrations and GMP plant inspections underway in various countries. This expansion is facilitated by the company's adherence to international manufacturing standards, including WHO-GMP and DPML (GMP) certifications from Côte d'Ivoire. These certifications enable Vellinton Healthcare to access and supply pharmaceutical products to these regions effectively.

Geographic Strategy

Vellinton Healthcare — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vellinton Healthcare's manufacturing facilities are designed to meet international standards, with plans to acquire certifications such as EU GMP, US FDA, and PIC/S to enhance their global market presence. The company has initiated business across regions such as Africa, Latin America, ASEAN, CIS, and MENA, with product registrations and GMP plant inspections underway in various countries. These efforts underscore the company's commitment to meeting the stringent regulatory requirements of these markets.

2WHO & EU GMP

Vellinton Healthcare has achieved WHO-GMP certification, ensuring that its manufacturing processes meet international quality standards. The company is actively pursuing additional certifications, including EU GMP, US FDA, and PIC/S, to further enhance its compliance with global regulatory requirements. These certifications are crucial for expanding the company's market reach and establishing trust with international partners and customers.

3CDSCO & Indian Regulatory

Vellinton Healthcare — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vellinton Healthcare operates in a competitive pharmaceutical industry, facing competition from both domestic and international manufacturers. The company's focus on small volume parenterals, beta-lactam antibiotics, cephalosporins, and ophthalmic preparations positions it in direct competition with other manufacturers specializing in these therapeutic areas. While specific market share data is not publicly available, Vellinton Healthcare's adherence to international manufacturing standards, including WHO-GMP and DPML (GMP) certifications from Côte d'Ivoire, enhances its competitiveness in global markets. The company's expansion into emerging markets such as Africa, Latin America, Southeast Asia, and the Middle East further intensifies competition, as these regions are also targeted by other pharmaceutical companies seeking growth opportunities.

2Key Differentiators

Vellinton Healthcare differentiates itself through its commitment to high-quality manufacturing, adherence to international standards, and strategic expansion into diverse geographic markets. The company's manufacturing facilities are designed to meet international standards, with plans to acquire certifications such as EU GMP, US FDA, and PIC/S to enhance their global market presence. Additionally, Vellinton Healthcare has initiated business across regions such as Africa, Latin America, ASEAN, CIS, and MENA, with product registrations and GMP plant inspections underway in various countries. These efforts underscore the company's proactive approach to quality assurance and market expansion.

Buyer Due Diligence Brief — Evaluating Vellinton Healthcare as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vellinton Healthcare has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's adherence to international manufacturing standards, including WHO-GMP and DPML (GMP) certifications from Côte d'Ivoire, reflects its commitment to quality assurance.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Vellinton Healthcare

How many pharmaceutical products does Vellinton Healthcare export from India?

Vellinton Healthcare exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Morphine ($32.7K), Biotin ($12.4K). Total export value is $45.1K.

What is Vellinton Healthcare's total pharmaceutical export value?

Vellinton Healthcare's total pharmaceutical export value is $45.1K, based on 6 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vellinton Healthcare cover?

Vellinton Healthcare exports across 2 therapeutic categories. The largest are Analgesics & Antipyretics (72.4%, 1 products), Vitamins & Supplements (27.6%, 1 products).

Get Full Vellinton Healthcare Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.